Sichuan Biokin PharmaceuticalLtd Third Quarter 2024 Earnings: CN¥1.50 loss per share (vs CN¥0.46 loss in 3Q 2023)
Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥109.8m (up 65% from 3Q 2023).
- Net loss: CN¥601.0m (loss widened by 222% from 3Q 2023).
- CN¥1.50 loss per share (further deteriorated from CN¥0.46 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sichuan Biokin PharmaceuticalLtd Earnings Insights
Looking ahead, revenue is expected to decline by 37% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in China are expected to grow by 13%.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are down 8.5% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Sichuan Biokin PharmaceuticalLtd (including 1 which doesn't sit too well with us).
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688506
Sichuan Biokin PharmaceuticalLtd
Engages in the research and development, production, and marketing of small molecule chemical, macromolecular biological, and antibody-drug conjugate drugs in China and internationally.
Flawless balance sheet with proven track record.